ValiRx plc (VAL) - Net Assets
Based on the latest financial reports, ValiRx plc (VAL) has net assets worth £3.01 Million GBP (≈ $4.04 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (£3.10 Million ≈ $4.16 Million USD) and total liabilities (£87.45K ≈ $117.43K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VAL tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | £3.01 Million |
| % of Total Assets | 97.18% |
| Annual Growth Rate | 6.1% |
| 5-Year Change | -17.66% |
| 10-Year Change | -13.61% |
| Growth Volatility | 342.62 |
ValiRx plc - Net Assets Trend (2001–2024)
This chart illustrates how ValiRx plc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of ValiRx plc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ValiRx plc (2001–2024)
The table below shows the annual net assets of ValiRx plc from 2001 to 2024. For live valuation and market cap data, see VAL stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | £3.92 Million ≈ $5.26 Million |
+34.84% |
| 2023-12-31 | £2.90 Million ≈ $3.90 Million |
-24.11% |
| 2022-12-31 | £3.83 Million ≈ $5.14 Million |
+12.06% |
| 2021-12-31 | £3.41 Million ≈ $4.59 Million |
-28.20% |
| 2020-12-31 | £4.76 Million ≈ $6.39 Million |
+113.90% |
| 2019-12-31 | £2.22 Million ≈ $2.99 Million |
-26.65% |
| 2018-12-31 | £3.03 Million ≈ $4.07 Million |
-3.86% |
| 2017-12-31 | £3.15 Million ≈ $4.23 Million |
+33.05% |
| 2016-12-31 | £2.37 Million ≈ $3.18 Million |
-47.73% |
| 2015-12-31 | £4.53 Million ≈ $6.09 Million |
+62.58% |
| 2014-12-31 | £2.79 Million ≈ $3.74 Million |
-13.69% |
| 2013-12-31 | £3.23 Million ≈ $4.34 Million |
-35.86% |
| 2012-12-31 | £5.04 Million ≈ $6.76 Million |
+13.85% |
| 2011-12-31 | £4.42 Million ≈ $5.94 Million |
+121.53% |
| 2010-12-31 | £2.00 Million ≈ $2.68 Million |
+120.18% |
| 2009-12-31 | £907.00K ≈ $1.22 Million |
-33.89% |
| 2008-12-31 | £1.37 Million ≈ $1.84 Million |
-17.84% |
| 2007-12-31 | £1.67 Million ≈ $2.24 Million |
-37.83% |
| 2006-12-31 | £2.69 Million ≈ $3.61 Million |
+1568.32% |
| 2006-03-31 | £161.00K ≈ $216.21K |
+179.31% |
| 2005-12-31 | £-203.00K ≈ $-272.61K |
-194.20% |
| 2004-12-31 | £-69.00K ≈ $-92.66K |
-202.99% |
| 2003-12-31 | £67.00K ≈ $89.97K |
+147.52% |
| 2002-12-31 | £-141.00K ≈ $-189.35K |
-114.07% |
| 2001-12-31 | £1.00 Million ≈ $1.35 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ValiRx plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2596479000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | £374.35K | 8.67% |
| Other Components | £42.43 Million | 982.88% |
| Total Equity | £4.32 Million | 100.00% |
ValiRx plc Competitors by Market Cap
The table below lists competitors of ValiRx plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TTL Beteiligungs- und Grundbesitz-AG
F:TTO
|
$3.05 Million |
|
STL Global Limited
NSE:SGL
|
$3.05 Million |
|
Devernois SA
PA:ALDEV
|
$3.05 Million |
|
Glacier Lake Resources Inc
V:GLI
|
$3.05 Million |
|
Zonetail Inc
V:ZONE
|
$3.04 Million |
|
Commander Resources Ltd
V:CMD
|
$3.04 Million |
|
VCI Global Limited Ordinary Share
NASDAQ:VCIG
|
$3.04 Million |
|
Copper Lake Resources Ltd
V:CPL
|
$3.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ValiRx plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,218,550 to 4,317,382, a change of 1,098,832 (34.1%).
- Net loss of 1,915,693 reduced equity.
- New share issuances of 3,374,744 increased equity.
- Other comprehensive income decreased equity by 1,684,576.
- Other factors increased equity by 1,324,357.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | £-1.92 Million | -44.37% |
| Share Issuances | £3.37 Million | +78.17% |
| Other Comprehensive Income | £-1.68 Million | -39.02% |
| Other Changes | £1.32 Million | +30.68% |
| Total Change | £- | 34.14% |
Book Value vs Market Value Analysis
This analysis compares ValiRx plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 5.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | £64.70 | £0.19 | x |
| 2002-12-31 | £-8.91 | £0.19 | x |
| 2003-12-31 | £4.23 | £0.19 | x |
| 2004-12-31 | £-13.01 | £0.19 | x |
| 2005-12-31 | £-1492.65 | £0.19 | x |
| 2006-12-31 | £4701.94 | £0.19 | x |
| 2007-12-31 | £880.60 | £0.19 | x |
| 2008-12-31 | £476.89 | £0.19 | x |
| 2009-12-31 | £111.53 | £0.19 | x |
| 2010-12-31 | £101.91 | £0.19 | x |
| 2011-12-31 | £73.11 | £0.19 | x |
| 2012-12-31 | £61.10 | £0.19 | x |
| 2013-12-31 | £29.12 | £0.19 | x |
| 2014-12-31 | £1842.33 | £0.19 | x |
| 2015-12-31 | £17.51 | £0.19 | x |
| 2016-12-31 | £5.09 | £0.19 | x |
| 2017-12-31 | £2.63 | £0.19 | x |
| 2018-12-31 | £0.85 | £0.19 | x |
| 2019-12-31 | £0.33 | £0.19 | x |
| 2020-12-31 | £0.13 | £0.19 | x |
| 2021-12-31 | £0.06 | £0.19 | x |
| 2022-12-31 | £0.05 | £0.19 | x |
| 2023-12-31 | £0.03 | £0.19 | x |
| 2024-12-31 | £0.03 | £0.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ValiRx plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3848.71%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.99x
- Recent ROE (-44.37%) is above the historical average (-92.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -535.06% | -552.88% | 0.62x | 1.57x | £-5.58 Million |
| 2002 | 0.00% | -16817.65% | 0.08x | 0.00x | £-2.84 Million |
| 2003 | -223.88% | 0.00% | 0.00x | 1.88x | £-156.70K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | £-338.10K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | £-113.70K |
| 2006 | -14.41% | -2996.38% | 0.00x | 1.05x | £-648.11K |
| 2007 | -73.42% | -2952.38% | 0.02x | 1.05x | £-1.41 Million |
| 2008 | -135.28% | -5987.10% | 0.02x | 1.30x | £-1.99 Million |
| 2009 | -159.10% | -18037.50% | 0.00x | 1.84x | £-1.53 Million |
| 2010 | 6.71% | 75.71% | 0.07x | 1.25x | £-65.70K |
| 2011 | -21.09% | -205.05% | 0.10x | 1.03x | £-1.38 Million |
| 2012 | -42.96% | -1000.58% | 0.04x | 1.05x | £-2.67 Million |
| 2013 | -80.40% | -2079.99% | 0.03x | 1.27x | £-2.92 Million |
| 2014 | -114.43% | -3609.07% | 0.02x | 1.31x | £-3.44 Million |
| 2015 | -47.56% | -2564.48% | 0.02x | 1.15x | £-2.56 Million |
| 2016 | -202.06% | 0.00% | 0.00x | 2.11x | £-4.98 Million |
| 2017 | -98.75% | 0.00% | 0.00x | 1.55x | £-3.46 Million |
| 2018 | -139.78% | 0.00% | 0.00x | 1.36x | £-4.68 Million |
| 2019 | -103.05% | 0.00% | 0.00x | 1.53x | £-2.66 Million |
| 2020 | -29.90% | 0.00% | 0.00x | 1.01x | £-1.96 Million |
| 2021 | -42.99% | 0.00% | 0.00x | 0.98x | £-1.91 Million |
| 2022 | -59.40% | 0.00% | 0.00x | 0.98x | £-2.81 Million |
| 2023 | -63.31% | -21226.05% | 0.00x | 0.97x | £-2.36 Million |
| 2024 | -44.37% | -3848.71% | 0.01x | 0.99x | £-2.35 Million |
Industry Comparison
This section compares ValiRx plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,460,727
- Average return on equity (ROE) among peers: -591.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ValiRx plc (VAL) | £3.01 Million | -535.06% | 0.03x | $3.05 Million |
| 4BASEBIO UK SOCIETAS (4BB) | $-492.00K | 0.00% | 0.00x | $989.13K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $155.87K |
| Arecor Therapeutics PLC (AREC) | $6.45 Million | 10.29% | 0.26x | $287.12K |
| Avacta Group PLC (AVCT) | $21.00K | -5252.38% | 9.24x | $3.91 Million |
| BSF Enterprise Plc (BSFA) | $4.86 Million | -30.89% | 0.08x | $15.23K |
| Bioventix (BVXP) | $6.58 Million | 38.84% | 0.05x | $1.16 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $937.00K | -418.46% | 0.23x | $137.45K |
| Amur Minerals Corporation (CRTX) | $22.23 Million | -6.94% | 0.04x | $64.52K |
| Fusion Antibodies PLC (FAB) | $1.12 Million | -231.17% | 0.84x | $165.94K |
| Faron Pharmaceuticals Oy (FARN) | $-15.16 Million | 0.00% | 0.00x | $602.85K |
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more